Stamaril™

BIOLOGICAL2 trials

Sponsors

GlaxoSmithKline

Conditions

Infections, StreptococcalMalaria

Phase 2

Safety and Immunogenicity Study of GSK Biologicals' Malaria Vaccine 257049, When Incorporated Into an EPI Regimen

CompletedNCT00436007

GlaxoSmithKlineMalaria

Start: 2007-04-30End: 2009-10-07Updated: 2018-08-16

Impact of GSK Biologicals' 2189242A Vaccine on Nasopharyngeal Carriage, Safety & Immunogenicity in Children & Infants

CompletedNCT01262872

GlaxoSmithKlineInfections, Streptococcal

Start: 2011-02-09End: 2013-03-18Updated: 2019-06-19

Related Papers

Immunogenicity and reactogenicity of ten-valent versus 13-valent pneumococcal conjugate vaccines among infants in Ho Chi Minh City, Vietnam: a randomised controlled trial.

2019-04-0838 citations

Immunogenicity of pneumococcal conjugate vaccine formulations containing pneumococcal proteins, and immunogenicity and reactogenicity of co-administered routine vaccines – A phase II, randomised, observer-blind study in Gambian infants

Vaccine2019-04-0823 citations

Efficacy of a novel, protein-based pneumococcal vaccine against nasopharyngeal carriage of Streptococcus pneumoniae in infants: A phase 2, randomized, controlled, observer-blind study

Vaccine2017-04-0480 citations

The effect of immunization schedule with the malaria vaccine candidate RTS,S/AS01E on protective efficacy and anti-circumsporozoite protein antibody avidity in African infants.

2015-02-1328 citations

Peripheral blood monocyte-to-lymphocyte ratio at study enrollment predicts efficacy of the RTS,S malaria vaccine: analysis of pooled phase II clinical trial data.

2013-08-2131 citations

Safety and efficacy of the RTS,S/AS01E candidate malaria vaccine given with expanded-programme-on-immunisation vaccines: 19 month follow-up of a randomised, open-label, phase 2 trial.

2011-07-22104 citations

Evaluation of the safety and immunogenicity of the RTS,S/AS01E malaria candidate vaccine when integrated in the expanded program of immunization.

2010-10-0152 citations